Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results

Chua, Terence C.; Robertson, Greg; Farrell, Rhonda; Yan, Tristan D.; Morris, David L.

doi:10.1007/s00432-009-0667-4

Cited by 158 publications

(104 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A retrospective study suggests that the combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is feasible and has potential benefits. A randomized trial is needed to establish its role in the management of these difficult cases (Chua, et al 2009). Similar results were reported in a pilot study of Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer.…”

Section: Hyperthermic Intraperitoneal Chemotherapysupporting

confidence: 53%

Management of Recurrent or Persistent Ovarian Cancer

Gennatas¹

2012

Ovarian Cancer - Clinical and Therapeutic Perspectives

View full text Add to dashboard Cite

Section: Hyperthermic Intraperitoneal Chemotherapysupporting

confidence: 53%

Management of Recurrent or Persistent Ovarian Cancer

Gennatas¹

2012

Ovarian Cancer - Clinical and Therapeutic Perspectives

View full text Add to dashboard Cite

“…31 As a combination therapy, complete debulking surgery and administration of HIPEC in EOC can show a morbidity rate ranging between 15 and 45% and a mortality up to 10%. 32 Our retrospective experience shows that EH + HIPEC is feasible. These data have to be validated in the large multicentric randomized study Chorine protocol with a homogenous population, in order to demonstrate the DFS and OS with a longer follow-up time adopting this surgical procedure.…”

Section: Discussionmentioning

confidence: 84%

Extra-peritoneal hysteroannessiectomy with eventual concomitant en bloc rectal resection and cytoreductive surgery in epithelial ovarian cancer (and other peritoneal surface malignancies): technical details

et al. 2017

View full text Add to dashboard Cite

Surgery allows the correct evaluation of the peritoneal dissemination of the epithelial ovarian cancer (EOC) and the removal of as much tumor as possible to maximize adjuvant chemotherapy. Neoadjuvant chemotherapy (NACT) and interval debulking surgery have been proposed as a reasonable alternative to primary complete cytoreductive surgery (CRS) in patients not fit for an initial extensive debulking surgery. Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has been offered as a promising therapeutic procedure to increase survival by treating the microscopic component of the neoplastic disease.Matherial and Method. 419 eligible patients with stage III-IV EOC were subjected to CRS, previous NACT in 343 patients, 20 of which with CRS combined with extraperitoneal hysterectomy (EH) + HIPEC. Purposes of our four years retrospective observational study are the revision of the surgical approaches to the EOC, a detailed report of the pelvic peritonectomy in association to hysteroannessiectomy (+/-consensual rectal resection) and the prospective review of the results.Conclusions. This study shows that EH + HIPEC is feasible. The detailed description of the technique here depicted could help to standardize this type of peritonectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The most serious condition that may develop in peritoneal metastasis is PC, which has an extremely poor prognosis (6,20,21). PC has been estimated to be responsible for 60% of all gastric cancer-associated mortalities, with peritoneal metastases in these patients considered terminal (6,20,21). Therapy consists mainly of palliative chemotherapy; long-term survival is considered poor, since systemic chemotherapy agents are unlikely to reach cytotoxic concentrations in peritoneal nodules (22)(23)(24)(25)(26)(27).…”

Section: Discussionmentioning

confidence: 99%

Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present study describes the use of bidirectional chemotherapy in the treatment of patients with gastric cancer and peritoneal carcinomatosis (PC), using newly developed response criteria for the treatment of malignant ascites. In addition, the association between effusion response and survival was analyzed. Between June 2010 and May 2014, patients affected by malignant ascites secondary to unresectable PC of gastric origin were treated with a combination of systemic and loco-regional chemotherapy. Cisplatin (75 mg/m 2 ) at an inflow temperature of 43˚C was infused intraperitoneally, and docetaxel (75 mg/m 2 ) was infused simultaneously via a peripheral vein, on day 1 every 3 weeks. The primary endpoint was overall survival rate, and the secondary endpoint was efficacy against malignant ascites using new response criteria. In total, 41 patients were enrolled, the majority of whom received 6 cycles of intraperitoneal chemotherapy in combination with hyperthermia. The majority of patients exhibited clinical regression of ascites and relief of associated symptoms. Malignant ascites disappeared [complete response (CR)] or decreased by 50% [partial response (PR)] in 73.2% of patients. No mortalities associated with the procedures occurred. The median survival time was 8.6 months, and the 1-year survival rate was 24.4%. As these new response criteria for the treatment of malignant ascites were found to be feasible, bidirectional chemotherapy may be the preferred strategy for the treatment of gastric cancer with PC. The CR, PR and non-PR groups showed significant differences in overall survival, indicating that decreased effusion was associated with improved patient survival.

show abstract

Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results

Abstract: Despite the heterogeneity of the studies reviewed, current evidence suggest that complete CRS and HIPEC may be a feasible option with potential benefits that are comparable with the current standard of care. A randomized trial is required to establish the role of HIPEC in ovarian cancer.

Cited by 158 publications

References 51 publications

Management of Recurrent or Persistent Ovarian Cancer

Management of Recurrent or Persistent Ovarian Cancer

Extra-peritoneal hysteroannessiectomy with eventual concomitant en bloc rectal resection and cytoreductive surgery in epithelial ovarian cancer (and other peritoneal surface malignancies): technical details

Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites

Contact Info

Product

Resources

About